MIRA Pharmaceuticals Inc. $(MIRA)$ has announced significant progress in its regulatory journey with the U.S. Securities and Exchange Commission $(SEC.UK)$ finalizing its review of the merger proxy related to MIRA's acquisition of SKNY Pharmaceuticals. With no comments from the SEC, MIRA is now moving toward shareholder approval and the final steps needed to complete the transaction. This acquisition includes SKNY-1, an investigational therapy targeting obesity and nicotine addiction. Additionally, MIRA's proprietary drug candidate, Mira-55, has shown promising preclinical results, matching morphine in pain relief without opioid risks, and has received confirmation from the U.S. Drug Enforcement Administration $(DEA)$ that it is not a controlled substance, facilitating further clinical development.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。